Alkermes Raises Acquisition Offer for Avadel Pharmaceuticals to $22.50 per Share
- Alkermes plc has increased its acquisition bid for Avadel Pharmaceuticals to $22.50 per share, including cash and CVR.
- The acquisition is approved and expected to finalize in Q1 2026, following evaluations of competing offers.
- Alkermes aims to enhance its CNS therapeutic portfolio through the acquisition of Avadel Pharmaceuticals.
### Alkermes Enhances Acquisition Bid for Avadel Pharmaceuticals
Alkermes plc has announced a significant increase in its bid to acquire Avadel Pharmaceuticals plc, offering a total transaction value of up to $22.50 per share. This revised offer consists of $21.00 in cash along with a non-transferable contingent value right (CVR) that could yield an additional $1.50 per share, pending the approval of Avadel's LUMRYZ™ by the U.S. Food and Drug Administration (FDA) for treating idiopathic hypersomnia in adults by the end of 2028. Avadel's valuation is estimated at approximately $2.37 billion, contingent on the approval milestone, showcasing Alkermes' strategic interest in expanding its therapeutic portfolio.
The boards of both companies have formally approved the transaction, which is set to finalize in the first quarter of 2026, subject to customary closing conditions. This development follows Avadel's prior engagement with H. Lundbeck A/S, which had submitted an unsolicited acquisition proposal on November 14, 2025. Initially considered a "Company Superior Proposal," Lundbeck's offer was ultimately deemed less favorable by Avadel's board after a thorough evaluation, allowing Alkermes' bid to take precedence. This swift strategic pivot underscores Avadel’s commitment to ensuring that its shareholders receive the best possible value.
Alkermes' enhanced offer highlights its ambitions to bolster its pipeline and solidify its position within the pharmaceutical landscape. The acquisition of Avadel is particularly significant as it could enhance Alkermes’ offerings in the central nervous system (CNS) therapeutic area. As both companies navigate the complexities inherent in the pharmaceutical sector, this merger signifies a critical step for Alkermes, potentially expanding its capabilities in addressing unmet medical needs.
In a related development, Halper Sadeh LLC, an investor rights law firm, is conducting an investigation into potential violations of federal securities laws concerning Avadel Pharmaceuticals and other companies involved in recent acquisition deals. Shareholders are encouraged to contact the firm to understand their rights as the acquisition process unfolds. Halper Sadeh aims to ensure that investors are adequately informed and receive fair compensation during these corporate transitions.